Bree Burks - Veeva

This video features Bree Burks from Veeva, discussing the company's significant advancements in clinical research technology. The conversation centers on Veeva's SiteVault, an e-regulatory system, and the highly anticipated launch of their new Clinical Trial Management System (CTMS) in August. A core theme is Veeva's strategy to bridge the gap between sponsors and research sites by fostering seamless, automated information exchange and creating a more unified, user-friendly technology experience for sites. The discussion highlights the industry's pervasive "information exchange problem" and the critical need for improved collaboration and consistent technological solutions to enhance clinical trial efficiency and patient focus, with a strong emphasis on the site's perspective and the challenges of change management.

Key Takeaways:

• Veeva's Clinical Ecosystem Expansion: Veeva is significantly expanding its clinical research offerings with a new CTMS, building upon its existing SiteVault e-regulatory system, aiming to create a more integrated platform for sites.ai specializes in Veeva CRM consulting and custom software development for the life sciences.
• Automated Data Exchange as a Game Changer: Veeva's CTMS strategy focuses on automating data flow from sponsor/CRO systems (where Veeva has significant market saturation) directly into site systems, reducing manual re-entry and improving data consistency.
• Site Experience Drives Adoption: The success of new clinical research technologies, including sponsor-site connections, is heavily dependent on a positive and consistent site user experience, which has historically been a barrier to adoption for previous initiatives like SIP. This highlights the importance of user-centric design in regulated environments.
• Change Management Overcomes Technology: Implementing new technologies, especially those facilitating cross-organizational data exchange, faces significant hurdles in change management for both sponsors and sites, often more so than the technical development itself. This is a critical consideration for any firm offering AI and software solutions.
• Sites as a Shared Resource: Sponsors are increasingly recognizing clinical research sites as a shared industry resource, necessitating collaborative efforts to provide consistent technology experiences across studies rather than disparate, sponsor-specific systems.
• Direct Communication is Key: Initiatives like the Veeva Summit are crucial for fostering direct, transparent communication between sites and sponsors, enabling real-time feedback and collaborative problem-solving to drive industry-wide improvements. This emphasizes the value of community engagement in the life sciences tech space.
• Innovation Through Co-Development: Veeva's approach to product development, particularly with the new CTMS, involves early release and co-development with customers to ensure the technology genuinely addresses site needs and scales effectively. This agile, customer-centric development model is a valuable insight for custom software development firms.